Molecular Human Reproduction, Vol 3, 1119-1123, Copyright © 1997 by Oxford University Press
AM Di Blasio, C Carniti, P Vigano, P Florio, F Petraglia and M Vignali
This study was designed to determine whether basic fibroblast growth factor
(bFGF) gene expression in human placenta varies as a function of
gestational age and to evaluate whether bFGF synthesis might be altered in
pathological pregnancies. Moreover, we also investigated whether human
placental cells express the bFGF receptor gene. The presence of mRNA for
bFGF and its receptor was demonstrated by reverse transcriptase-polymerase
chain reaction (RT-PCR) performed on total RNA derived from human placental
cells at different times of culture. Levels of bFGF mRNA were determined by
competitive RT-PCR in human placental tissues collected at the beginning
and at the end of pregnancy. Competitive RT-PCR was also employed to
evaluate bFGF synthesis in term placentas derived from pregnancies
complicated by diabetes. mRNA for both bFGF and its receptor were
demonstrated in human placenta starting as early as 8 weeks of pregnancy.
Values of bFGF mRNA were significantly higher in first trimester compared
with term placentas. Term placentas derived from pregnancies associated
with type I diabetes expressed levels of bFGF mRNA higher than those
present in normal term placentas. These data demonstrate that bFGF and its
receptor are synthesized in human placental cells throughout gestation.
Moreover, bFGF gene expression is developmentally regulated. Finally, bFGF
might also be partially responsible for the placental alterations observed
in pregnancies complicated by diabetes.
JOURNAL ARTICLE
Basic fibroblast growth factor messenger ribonucleic acid levels in human placentas from normal and pathological pregnancies
Molecular Biology Laboratory, Istituto Auxologico Italiano Milano, Italy.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. Kumar, Z.-R. Liu, L. Thapa, and R.-Y. Qin Anti-angiogenic effects of somatostatin receptor subtype 2 on human pancreatic cancer xenografts Carcinogenesis, November 1, 2004; 25(11): 2075 - 2081. [Abstract] [Full Text] [PDF] |
||||
